TABLE 1.
Baseline characteristics of study population
| Evogliptin (n = 102) | Linagliptin (n = 105) | P‐value | |
|---|---|---|---|
| Age (years) | 56.6 (10.7) | 55.6 (10.2) | .690 a |
| Sex (men), n (%) | 61 (59.8) | 54 (51.4) | .225 b |
| BMI (kg/m2) | 26.0 (3.3) | 26.2 (3.5) | .559 a |
| Obesity c , n (%) | 59 (57.8) | 60 (57.1) | .919 b |
| Duration of diabetes (years) | 4.1 (4.4) | 3.7 (4.1) | .564 a |
| Duration of diabetes ≤4 weeks, n (%) | 26 (25.5) | 23 (21.9) | .544 b |
Abbreviation: BMI, body mass index.
a
P‐values were derived from a Wilcoxon rank‐sum test.
b
P‐values were derived from a Chi‐square test.
c
BMI > 25 kg/m2.